Lower urinary tract symptoms

Clinics in Geriatric Medicine

Volumn 26, Issue 2, 2010, Pages 249-260

  Gammack, Julie K ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Erectile dysfunction; Lower urinary tract symptoms; LUTS; Older men

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARGIPRESSIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; OXYBUTYNIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TENOXICAM; TESTOSTERONE; TOLTERODINE;

ANDROGEN THERAPY; ANXIETY; BLADDER FUNCTION; BLOOD CELL COUNT; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; NEUROLOGIC EXAMINATION; OVERACTIVE BLADDER; PATIENT EDUCATION; PELVIC FLOOR MUSCLE TRAINING; PHYSICAL EXAMINATION; POSTMICTURITION DRIBBLE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL HEALTH; TREATMENT OUTCOME; URINALYSIS; URINARY DYSFUNCTION; URINE FLOW RATE; URINE VOLUME; VASOPRESSIN BLOOD LEVEL; XEROSTOMIA;

ADRENERGIC ANTAGONISTS; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; QUALITY OF LIFE; URINATION DISORDERS; UROLOGIC DISEASES;

EID: 77953163983     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2010.02.006     Document Type: Review

References (55)

1. Coyne K.S., Sexton C.C., Thompson C.L., et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009, 104(3):352-360.
2. Irwin D.E., Milsom I., Hunsakaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50(6):1306-1314.
3. Marszalek M., Wehrberger C., Temml C., et al. Chronic pelvic pain and lower urinary tract symptoms in both sexes: analysis of 2749 participants of an Urban Health Screening Project. Eur Urol 2009, 55:499-508.
4. Barry M.J., Fowler F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measuring Committee of the American Urological Association. J Urol 1992, 148:1549.
5. Homma Y., Kakizaki H., Gotoh M., et al. Epidemiologic survey on urination. The Journal of The Japan Neurogenic Bladder Society 2003, 14:266-277.
6. Coyne K.S., Wein A.J., Tubaro A., et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009, 103(Suppl 3):4-11.
7. Coyne K.S., Kaplan S.A., Chapple C.R., et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS (p 24-32). BJU Int 2009, 103(s3). 1-57.
8. Parsons J.K., Mouget J., Lambert L., et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009, 104(1):63-68.
9. Wein A.J., Coyne K.S., Tubaro A., et al. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int 2009, 103(Suppl 3):33-41.
10. Barqawi A., O'Donnell C., Kumar R., et al. Correlation between LTUC (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population. Int J Impot Res 2005, 17(4):370-374.
11. Truzzi J.C., Almeida F.M., Nunes E.C., et al. Residual urinary volume and urinary tract infection-when are they linked?. J Urol 2008, 180(1):182-185.
12. Ulleryd P., Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis 2003, 35(1):34-39.
13. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for HIV, STD and TB Prevention (NCHSTP), et al. Prevention, sexually transmitted disease morbidity for selected STDs by age, race/ethnicity and gender 1996-2008 CDC WONDER On-line Database, November 2009. Available at:, Accessed January 25, 2010. http://wonder.cdc.gov/std-std-v2008-race-age.html.
14. Boyce C.J., Pickhardt P.J., Lawrence E.M., et al. Prevalence of urolithiasis in asymptomatic adults: objective determination using low dose noncontrast computerized tomography. J Urol 2010, 183(3):1017-1021.
15. Nicolle L.E., Orr P., Duckworth H., et al. Gross hematuria in residents of long-term-care facilities. Am J Med 1993, 94(6):611-618.
16. Mebust W.K., Holtgrewe H.L., Cockett A.T.K., et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989, 141:243.
17. Litwin M.S., McNaughton-Collins M., Fowler F.J., et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. J Urol 1999, 162:369-375.
18. Bartoletti B., Cai T., Mondaini N., et al. Prevalence, incidence estimation risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 2007, 178:2411-2415.
19. Clemens J.Q., Brown S.O., Calhoun E.A. Mental health diagnoses in patients with interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome: a case/control study. J Urol 2008, 180(4):1378-1382.
20. Ye Z.Q., Lan R.Z., Yang W.M., et al. Tamsulosin treatment of chronic non-bacterial prostatitis. J Int Med Res 2008, 36:44-52.
21. Blanker M.H., Bernsen R.M., Bosch J.L., et al. Relation between nocturnal voiding frequency and nocturnal urine production in older men: a population-based study. Urology 2002, 60(4):612-616.
22. Blanker MH, Bernsen R, Bosch R, et-al. Normal values and determinants of circadian urine production in older men: a population based study. J Urol 2002;168(4 Pt 1):1453-7.
23. Hirayama A., Fujimoto K., Akiyama T., et al. Decrease in nocturnal urinary levels of arginine vasopressin in patients with nocturnal polyuria. Urology 2006, 68(1):19-23.
24. Song H.J., Bae J.M. Prevalence of urinary incontinence and lower urinary tract symptoms for community-dwelling elderly 85 years of age and older. J Wound Ostomy Continence Nurs 2007, 34(5):535-541.
25. Anger J.T., Saigal C.S., Stothers L., et al. Urologic Diseases of America Project. The prevalence of urinary incontinence among community dwelling men: results from the National Health and Nutrition Examination survey. J Urol 2006, 176(5):2103-2108.
26. Offermans M.P., Du Moulin M.F., Hamers J.P., et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn 2009, 28(4):288-294.
27. Krivoborodov G.G., Mazo E.B., Efremov N.S. Urologiia 2009, 1:13-16. [in Russian].
28. Hanai T., Matsumoto S., Shimizu N., et al. Nippon Hinyokika Gakkai Zasshi 2008, 99(7):723-728. [in Japanese].
29. Dorey G., Speakman M., Feneley R., et al. Pelvic floor exercises for treating post-micturition dribble in men with erectile dysfunction: a randomized controlled trial. Urol Nurs 2004, 24(6):490-497. 512.
30. Paterson J., Pinnock C.B., Marshall V.R. Pelvic floor exercises as a treatment for post-micturition dribble. Br J Urol 1997, 79(6):892-897.
31. Dong Z., Wang Z., Yang K., et al. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med 2009, 55(4):129-136.
32. Wilt T.J., Mac Donald R., Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003, (1). CD002081.
33. Nabi G., Cody J.D., Ellis G., et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006, (4). CD003781.
34. Karazindiyanoglu S., Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008, 11(3):146-149.
35. Kalinchenko S., Vishnevskiy E.L., Koval A.N., et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008, 11(2):57-61.
36. Haider A., Gooren L.J., Padungtod P., et al. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009, 41(1):7-13.
37. Blake-James B.T., Rashidian A., Ikeda Y., et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2007, 99(1):85-96.
38. Novara G., Galfano A., Ficarra V., et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006, 50(4):675-683.
39. McVary K.T., Monnig W., Camps J.L., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071-1077.
40. Stief C.G., Porst H., Neuser D., et al. A randomized placebo controlled study to assess the efficacy of twice daily Vardenafil in the treatment of LUTS secondary to BPH. Eur Urol 2008, 53:1236-1244.
41. McVary K.T., Roehrborn C.G., Kaminetsky J.C., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401-1407.
42. Roehrborn C.G., McVary K.T., Elion-Mboussa A., et al. Tadalafil administered once a day in the treatment of men with LUTS secondary to BPH; a dose-finding study. J Urol 2008, 180:1228-1234.
43. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349(25):2387-2398.
44. Kaplan S.A., McConnell J.D., Roehrborn C.G., et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006, 175(1):217-220.
45. Roehrborn C.G., Siami P., Barkin J., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 2009, 57(1):123-131.
46. Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Eur Urol 2008, 179(2):616-621.
47. MacDiarmid S.A., Peters K.M., Chen A., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008, 83(9):1002-1010.
48. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296(19):2319-2328.
49. Kaplan S.A., Roehrborn C.G., Chancellor M., et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008, 102(9):1133-1139.
50. Rovner S., Kreder K., Sussman D.O., et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008, 180:1034-1041.
51. Ozdemir I., Bozkurt O., Demir O., et al. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009, 74(2):431-435.
52. Yassin A., Diede H.-E. Combination therapy: alpha1-adrenoceptor blockade and tadalafil in BPH population. Int J Impot Res 2003, 15(Suppl 6):2-5.
53. Chung B.H., Lee J.Y., Lee S.H., et al. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009, 21(2):122-128.
54. Bechara A., Romano S., Casabé A., et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008, 5(9):2170-2178.
55. Kaplan S.A., Gonzalez R.R., Te A.E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007, 51(6):1717-1723.